Cited by 326Cancer Immunotherapy and BiomarkersPituitary Gland Disorders and TreatmentsAdrenal Hormones and Disorders

The DOI matches its Crossref record; 88 of the 88 references it cites were found in a registry or an index.

Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights

Faje, Alexander·2016·Pituitary

Open this paper in CoChat — free account

Abstract

Introduction Advances in immunotherapy have transformed the management of metastatic melanoma and generated encouraging results in the treatment of other malignancies. Autoimmune side effects from these agents, termed immune-related adverse events (IRAEs), are diverse and can include multiple endocrinopathies. Ipilimumab-induced hypophysitis (IH) is a recently recognized endocrine IRAE.Methods This review summarizes published data and experience from our center on the incidence, presentation and management, and proposed mechanisms for immunotherapy-related hypophysitis, with a focus on patients treated with ipilimumab (Ipi).Conclusion Hypophysitis occurs in a significant minority of patients treated with Ipi, in contrast to the relative rarity of idiopathic autoimmune hypophysitis or hypophysitis after treatment with other immunotherapies. Recently published cohorts have described the clinical presentation and management of IH and longitudinal outcomes in these patients. Additional studies with Ipi and other emerging agents have helped identify potential risk factors for the development of immunotherapy-related hypophysitis and possible underlying mechanisms for IH. Clarification of the mechanism(s) for IH may enhance our understanding of idiopathic autoimmune hypophysitis and could have potential therapeutic applications.

Integrity signals

Registry

Crossref · 10.1007/s11102-015-0671-4

Cites

88 of 88 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945 · cited 2×
“treatment with anti-PD-1 or anti-PD-L1 agents is more common than hypophysitis and occurs in approximately 5–10 % of patients [20–28].”
Background
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406498 · Cited by 4,286
Nivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230

Show all 88 references

Sorted by citations

Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance
Martins, F., Sofiya, L., Sykiotis, G. P., Lamine, F., Maillard, M., Fraga, M., Shabafrouz, K., Ribi, C., Cairoli, A., Guex-Crosier, Y., et al. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0218-0 · Cited by 2,314
Immune-related adverse events with immune checkpoint blockade: a comprehensive review
Michot, J. M., Bigenwald, C., Champiat, S., Collins, M., Carbonnel, F., Postel-Vinay, S., Berdelou, A., Varga, A., Bahleda, R., Hollebecque, A., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2015.11.016 · Cited by 2,127
Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group
on behalf of the Society for Immunotherapy of Cancer Toxicity Management Working Group, Puzanov, I., Diab, A., Abdallah, K., Bingham, C. O., Brogdon, C., Dadu, R., Hamad, L., Kim, S., Lacouture, M. E., et al. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0300-z · Cited by 1,992
Society for immunotherapy of cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events
Brahmer, J. R., Abu-Sbeih, H., Ascierto, P. A., Brufsky, J., Cappelli, L. C., Cortazar, F. B., Gerber, D. E., Hamad, L., Hansen, E., Johnson, D. B., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002435 · Cited by 917
Cancer immunotherapy—immune checkpoint blockade and associated endocrinopathies.
Byun, D. J., Wolchok, J. D., Rosenberg, L. M., & Girotra, M. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.205 · Cited by 685
Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints
Chang, L., Barroso‐Sousa, R., Tolaney, S. M., Hodi, F. S., Kaiser, U. B., & Min, L. (2018) · Endocrine Reviews · doi:10.1210/er.2018-00006 · Cited by 550
High‐dose glucocorticoids for the treatment of ipilimumab‐induced hypophysitis is associated with reduced survival in patients with melanoma
Faje, A. T., Lawrence, D., Flaherty, K., Freedman, C., Fadden, R., Rubin, K., Cohen, J., & Sullivan, R. J. (2018) · Cancer · doi:10.1002/cncr.31629 · Cited by 486
Self-citation
Hypophysitis Secondary to Cytotoxic T-Lymphocyte–Associated Protein 4 Blockade
Caturegli, P., Dalmazi, G. D., Lombardi, M., Grosso, F., Larman, H. B., Larman, T., Taverna, G. G., Cosottini, M., & Lupi, I. (2016) · American Journal Of Pathology · doi:10.1016/j.ajpath.2016.08.020 · Cited by 391
Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma
Sangro, B., Chan, S. L., Meyer, T., Reig, M., El-Khoueiry, A. B., & Galle, P. R. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.10.021 · Cited by 299
Pembrolizumab-Induced Thyroiditis: Comprehensive Clinical Review and Insights Into Underlying Involved Mechanisms
Delivanis, D. A., Gustafson, M. P., Bornschlegl, S., Merten, M. M., Kottschade, L., Withers, S., Dietz, A. B., & Ryder, M. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-00448 · Cited by 278
Adrenal insufficiency
Hahner, S., Ross, R. J., Arlt, W., Bancos, I., Burger-Stritt, S., Torpy, D. J., Husebye, E. S., & Quinkler, M. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00252-7 · Cited by 223
Imaging of Cancer Immunotherapy: Current Approaches and Future Directions
Nishino, M., Hatabu, H., & Hodi, F. S. (2018) · Radiology · doi:10.1148/radiol.2018181349 · Cited by 218
Endocrine side effects of cancer immunotherapy
Cukier, P., Santini, F. C., Scaranti, M., & Hoff, A. O. (2017) · Endocrine-Related Cancer · doi:10.1530/erc-17-0358 · Cited by 177
Hypophysitis secondary to nivolumab and pembrolizumab is a clinical entity distinct from ipilimumab-associated hypophysitis
Faje, A. T., Reynolds, K. L., Zubiri, L., Lawrence, D. P., Cohen, J. V., Sullivan, R. J., Nachtigall, L. B., & Tritos, N. A. (2019) · European Journal of Endocrinology · doi:10.1530/eje-19-0238 · Cited by 180
The hypothalamus-pituitary-thyroid (HPT)-axis and its role in physiology and pathophysiology of other hypothalamus-pituitary functions
Feldt-Rasmussen, U., Effraimidis, G., & Klose, M. (2021) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2021.111173 · Cited by 170
Characterization of Thyroid Disorders in Patients Receiving Immune Checkpoint Inhibition Therapy
Lee, H., Hodi, F. S., Giobbie-Hurder, A., Ott, P. A., Buchbinder, E. I., Haq, R., Tolaney, S., Barroso-Sousa, R., Zhang, K., Donahue, H., et al. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0208 · Cited by 161
Immune checkpoint inhibitor toxicities
Marin-Acevedo, J. A., Chirila, R. M., & Dronca, R. S. (2019) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2019.03.012 · Cited by 160
Hypophysitis, the Growing Spectrum of a Rare Pituitary Disease
Langlois, F., Varlamov, E. V., & Fleseriu, M. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab672 · Cited by 155
Central hypothyroidism — a neglected thyroid disorder
Beck-Peccoz, P., Rodari, G., Giavoli, C., & Lania, A. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.47 · Cited by 140
The spectrum, incidence, kinetics and management of endocrinopathies with immune checkpoint inhibitors for metastatic melanoma
Scott, E. S., Long, G. V., Guminski, A., Clifton-Bligh, R. J., Menzies, A. M., & Tsang, V. H. (2018) · European Journal of Endocrinology · doi:10.1530/eje-17-0810 · Cited by 142
French Endocrine Society guidance on endocrine side effects of immunotherapy
Castinetti, F., Albarel, F., Archambeaud, F., Bertherat, J., Bouillet, B., Buffier, P., Briet, C., Cariou, B., Caron, P., Chabre, O., et al. (2019) · Endocrine Related Cancer · doi:10.1530/erc-18-0320 · Cited by 140
MECHANISMS IN ENDOCRINOLOGY: Hypophysitis: diagnosis and treatment
Joshi, M., Whitelaw, B., & Carroll, P. (2018) · European Journal of Endocrinology · doi:10.1530/eje-17-0009 · Cited by 140
Immune Checkpoints as Therapeutic Targets in Autoimmunity
Paluch, C., Santos, A. M., Anzilotti, C., Cornall, R. J., & Davis, S. J. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02306 · Cited by 142
Endocrinological side-effects of immune checkpoint inhibitors
Torino, F., Corsello, S. M., & Salvatori, R. (2016) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000293 · Cited by 138
Pituitary Dysfunction Induced by Immune Checkpoint Inhibitors Is Associated with Better Overall Survival in Both Malignant Melanoma and Non-Small Cell Lung Carcinoma: A Prospective Study
Kobayashi, T., Iwama, S., Yasuda, Y., Okada, N., Okuji, T., Ito, M., Onoue, T., Goto, M., Sugiyama, M., Tsunekawa, T., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000779 · Cited by 132
Hypophysitis induced by immune checkpoint inhibitors: a 10-year assessment
Dalmazi, G. D., Ippolito, S., Lupi, I., & Caturegli, P. (2019) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2019.1701434 · Cited by 134
Increased expression of programmed death ligand 1 (PD-L1) in human pituitary tumors
Mei, Y., Bi, W. L., Greenwald, N. F., Du, Z., Agar, N. Y. R., Kaiser, U. B., Woodmansee, W. W., Reardon, D. A., Freeman, G. J., Fecci, P. E., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.12088 · Cited by 127
The biomarkers related to immune related adverse events caused by immune checkpoint inhibitors
Jia, X., Geng, L., Jiang, P., Xu, H., Nan, K., Yao, Y., Jiang, L., Sun, H., Qin, T., & Guo, H. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01749-x · Cited by 120
Management of side effects of immune checkpoint blockade by anti‐CTLA‐4 and anti‐PD‐1 antibodies in metastatic melanoma
Kähler, K. C., Hassel, J. C., Heinzerling, L., Loquai, C., Mößner, R., Ugurel, S., Zimmer, L., & Gutzmer, R. (2016) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.13047 · Cited by 120
Hypophysitis: Evaluation and Management
Faje, A. T. (2016) · Clinical Diabetes and Endocrinology · doi:10.1186/s40842-016-0034-8 · Cited by 120
Detection of immune-related adverse events by medical imaging in patients treated with anti-programmed cell death 1
Mekki, A., Dercle, L., Lichtenstein, P., Marabelle, A., Michot, J., Lambotte, O., Pavec, J. L., Martin, E. D., Balleyguier, C., Champiat, S., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.03.006 · Cited by 118
Revisitation of autoimmune hypophysitis: knowledge and uncertainties on pathophysiological and clinical aspects
Bellastella, G., Maiorino, M. I., Bizzarro, A., Giugliano, D., Esposito, K., Bellastella, A., & Bellis, A. D. (2016) · Pituitary · doi:10.1007/s11102-016-0736-z · Cited by 117
Endocrine dysfunction induced by immune checkpoint inhibitors: Practical recommendations for diagnosis and clinical management
Barroso‐Sousa, R., Ott, P. A., Hodi, F. S., Kaiser, U. B., Tolaney, S. M., & Min, L. (2018) · Cancer · doi:10.1002/cncr.31200 · Cited by 122
Nivolumab-induced hypophysitis in a patient with advanced malignant melanoma
Okano, Y., Satoh, T., Horiguchi, K., Toyoda, M., Osaki, A., Matsumoto, S., Tomaru, T., Nakajima, Y., Ishii, S., Ozawa, A., et al. (2016) · Endocrine Journal · doi:10.1507/endocrj.ej16-0161 · Cited by 114
Autoimmune endocrine dysfunctions associated with cancer immunotherapies
Ferrari, S. M., Fallahi, P., Elia, G., Ragusa, F., Ruffilli, I., Patrizio, A., Galdiero, M. R., Baldini, E., Ulisse, S., Marone, G., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20102560 · Cited by 107
Neurological Adverse Events Associated with Immune Checkpoint Inhibitors: Diagnosis and Management
Astaras, C., Micheli, R. D., Moura, B. G., Hundsberger, T., & Hottinger, A. F. (2018) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-018-0810-1 · Cited by 109
Anti–PD-L1 Treatment Induced Central Diabetes Insipidus
Zhao, C. N., Tella, S. H., Rivero, J. D., Kommalapati, A., Ebenuwa, I., Gulley, J. L., Strauss, J., & Brownell, I. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-01905 · Cited by 103
New insight in endocrine-related adverse events associated to immune checkpoint blockade
Elia, G., Ferrari, S. M., Galdiero, M. R., Ragusa, F., Paparo, S. R., Ruffilli, I., Varricchi, G., Fallahi, P., & Antonelli, A. (2019) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2019.101370 · Cited by 108
Predicting Response to Immunotherapy by Evaluating Tumors, Lymphoid Cell-Rich Organs, and Immune-Related Adverse Events Using FDG-PET/CT
Nobashi, T., Baratto, L., Reddy, S. A., Srinivas, S., Toriihara, A., Hatami, N., Yohannan, T. K., & Mittra, E. (2019) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000002453 · Cited by 101
The Role of 18F-FDG PET/CT and PET/MRI in Pancreatic Ductal Adenocarcinoma
Yeh, R., Dercle, L., Garg, I., Wang, Z. J., Hough, D. M., & Goenka, A. H. (2017) · Abdominal Radiology · doi:10.1007/s00261-017-1374-2 · Cited by 100
Immunotherapy toxicity: identification and management
Gumusay, O., Callan, J., & Rugo, H. S. (2022) · Breast Cancer Research and Treatment · doi:10.1007/s10549-021-06480-5 · Cited by 98
MANAGEMENT OF ENDOCRINE DISEASE: Immune check point inhibitors-induced hypophysitis
Albarel, F., Castinetti, F., & Brue, T. C. (2019) · European Journal of Endocrinology · doi:10.1530/eje-19-0169 · Cited by 92
Adverse Effects of Immune Checkpoint Therapy in Cancer Patients Visiting the Emergency Department of a Comprehensive Cancer Center
Majzoub, I. E., Qdaisat, A. Z., Thein, K. Z., Win, M. A., Han, M. M., Jacobson, K. L., Chaftari, P. S., Prejean, M., Reyes‐Gibby, C. C., & Yeung, S. J. (2018) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2018.04.019 · Cited by 91
Isolated ACTH deficiency induced by cancer immunotherapy: a systematic review
Iglesias, P., Sánchez, J. C., & Díez, J. J. (2021) · Pituitary · doi:10.1007/s11102-021-01141-8 · Cited by 90
Oncologic emergencies and urgencies: A comprehensive review
Rothberg, B. E. G., Quest, T. E., Yeung, S. J., Pelosof, L. C., Gerber, D. E., Seltzer, J. A., Bischof, J. J., Thomas, C. R., Akhter, N., Mamtani, M., et al. (2022) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21727 · Cited by 95
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer
Emens, L. A., Adams, S., Cimino‐Mathews, A., Disis, M. L., Gatti-Mays, M. E., Ho, A. Y., Kalinsky, K. M., McArthur, H. L., Mittendorf, E. A., Nanda, R., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002597 · Cited by 84
Neurotoxicity associated with cancer immunotherapy: immune checkpoint inhibitors and chimeric antigen receptor T-cell therapy
Perrinjaquet, C., Desbaillets, N., & Hottinger, A. F. (2019) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000686 · Cited by 70
Cancer immunotherapy-induced endocrinopathies: Clinical behavior and therapeutic approach
Iglesias, P. (2017) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2017.08.019 · Cited by 70
DIAGNOSIS OF ENDOCRINE DISEASE: Expanding the cause of hypopituitarism
Pekić, S., & POPOVIC, V. M. (2017) · European Journal of Endocrinology · doi:10.1530/eje-16-1065 · Cited by 69
A review of serious adverse effects under treatment with checkpoint inhibitors
Heinzerling, L., & Goldinger, S. M. (2017) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000358 · Cited by 67
The Progress of Immunotherapy in Refractory Pituitary Adenomas and Pituitary Carcinomas
Dai, C., Liang, S., Sun, B., & Kang, J. P. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.608422 · Cited by 67
Immune‑related adverse events during anticancer immunotherapy: Pathogenesis and management (Review)
Stucci, L. S., Palmirotta, R., Passarelli, A. M., Silvestris, E., Argentiero, A., Lanotte, L., Acquafredda, S., Todisco, A., & Silvestris, F. (2017) · Oncology Letters · doi:10.3892/ol.2017.6919 · Cited by 67
Isolated autoimmune adrenocorticotropic hormone deficiency: From a rare disease to the dominant cause of adrenal insufficiency related to check point inhibitors
Percik, R., Shlomai, G., Tirosh, A., Tirosh, A., Leibowitz‐Amit, R., Eshet, Y., Greenberg, G., Merlinsky, A., Barhod, E., Steinberg‐Silman, Y., et al. (2019) · Autoimmunity Reviews · doi:10.1016/j.autrev.2019.102454 · Cited by 64
Immune checkpoint inhibitors in urothelial cancer: recent updates and future outlook
Gopalakrishnan, D., Koshkin, V. S., Ornstein, M. C., Papatsoris, A., & Grivas, P. D. (2018) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s158753 · Cited by 62
Adverse Events in Cancer Immunotherapy
Abdel‐Wahab, N., Alshawa, A., & Suarez-Almazor, M. E. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-53156-4_8 · Cited by 60
Revolutionary Cancer Therapy for Personalization and Improved Efficacy: Strategies to Overcome Resistance to Immune Checkpoint Inhibitor Therapy
Almawash, S. (2025) · Cancers · doi:10.3390/cancers17050880 · Cited by 69
Endocrine‐related adverse events associated with immune‐checkpoint inhibitors in patients with melanoma
Kassi, E. N., Angelousi, A. G., Asonitis, N., Diamantopoulos, P. T., Anastasopoulou, A. N., Papaxoinis, G., Kokkinos, M., Giovannopoulos, I., Kyriakakis, G., Petychaki, F., et al. (2019) · Cancer Medicine · doi:10.1002/cam4.2533 · Cited by 58
Cancer immunotherapy-associated hypophysitis
Solinas, C., Porcu, M., Silva, P. D., Musi, M., Aspeslagh, S., Scartozzi, M., Willard-Gallo, K. E., Mariotti, S., & Saba, L. (2018) · Seminars in Oncology · doi:10.1053/j.seminoncol.2018.09.002 · Cited by 59
The Changing Clinical Spectrum of Hypophysitis
Chiloiro, S., Capoluongo, E., Tartaglione, T., Giampietro, A., Bianchi, A., Giustina, A., Pontecorvi, A., & Marinis, L. D. (2019) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2019.06.004 · Cited by 56
Immunotherapy-related adverse effects on 18F-FDG PET/CT imaging
Gandy, N., Arshad, M., Wallitt, K. L., Dubash, S., Khan, S., & Barwick, T. D. (2020) · British Journal of Radiology · doi:10.1259/bjr.20190832 · Cited by 55
Programmed death-1 pathway blockade produces a synergistic antitumor effect: combined application in ovarian cancer
Zhu, X., & Lang, J. (2017) · Journal of Gynecologic Oncology · doi:10.3802/jgo.2017.28.e64 · Cited by 56
Autoimmune Endocrinopathies: An Emerging Complication of Immune Checkpoint Inhibitors
Quandt, Z., Young, A., Perdigoto, A. L., Herold, K. C., & Anderson, M. S. (2020) · Annual Review of Medicine · doi:10.1146/annurev-med-050219-034237 · Cited by 53
Case Report: A Case of Pituitary Carcinoma Treated With Sequential Dual Immunotherapy and Vascular Endothelial Growth Factor Inhibition Therapy
Lamb, L. S., Sim, H., & McCormack, A. I. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.576027 · Cited by 48
Immunotherapy-induced endocrinopathies: assessment, management and monitoring
Nogueira, E. F., Newsom‐Davis, T., & Morganstein, D. L. (2019) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018819896182 · Cited by 48
Hypophysitis and Secondary Adrenal Insufficiency From Immune Checkpoint Inhibitors: Diagnostic Challenges and Link With Survival
Johnson, J. N., Goldner, W. S., Abdallah, D., Qiu, F., Ganti, A. K., & Kotwal, A. (2023) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2022.7098 · Cited by 47
Combination immune checkpoint inhibitor therapy nivolumab and ipilimumab associated with multiple endocrinopathies
Gunawan, F., George, E., & Roberts, A. (2018) · Endocrinology Diabetes and Metabolism Case Reports · doi:10.1530/edm-17-0146 · Cited by 47
Prevalence of hypophysitis in a cohort of patients with metastatic melanoma and prostate cancer treated with ipilimumab
Brilli, L., Danielli, R., Ciuoli, C., Calabrò, L., Giacomo, A. M. D., Cerase, A., Paffetti, P., Sestini, F., Porcelli, B., Maio, M., et al. (2017) · Endocrine · doi:10.1007/s12020-017-1289-2 · Cited by 45
American Association of Clinical Endocrinology Disease State Clinical Review: Evaluation and Management of Immune Checkpoint Inhibitor-Mediated Endocrinopathies: A Practical Case-Based Clinical Approach
Yuen, K. C. J., Samson, S. L., Bancos, I., Gosmanov, A. R., Jasim, S., Fecher, L. A., & Weber, J. S. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.04.010 · Cited by 46
Reassessing Patterns of Response to Immunotherapy with PET: From Morphology to Metabolism
Costa, L. B., Queiroz, M. A., Barbosa, F. D. G., Nunes, R. F., Zaniboni, E. C., Ruiz, M. F. D. C. M., Jardim, D. L. F., Marin, J. F. G., Cerri, G. G., & Buchpiguel, C. A. (2020) · Radiographics · doi:10.1148/rg.2021200093 · Cited by 44
Endocrine toxicity of immune checkpoint inhibitors: essential crosstalk between endocrinologists and oncologists
Illouz, F., Briet, C., Cloix, L., Corre, Y. L., Baize, N., Urban, T., Martin, L., & Rodien, P. (2017) · Cancer Medicine · doi:10.1002/cam4.1145 · Cited by 44
Isolated Adrenocorticotropin Deficiency due to Nivolumab-induced Hypophysitis in a Patient with Advanced Lung Adenocarcinoma: A Case Report and Literature Review
Ohara, N., Ohashi, K., Fujisaki, T., Oda, C., Ikeda, Y., Yoneoka, Y., Hashimoto, T., Hasegawa, G., Suzuki, K. T., & Takada, T. (2017) · Internal Medicine · doi:10.2169/internalmedicine.9074-17 · Cited by 42
Cancer Immunotherapy-Associated Hypophysitis
Castillero, F., Castillo, O., Jiménez, G. J., Fallas-Ramirez, J.-M., Álvarez, M. P. P., & Arrieta, O. G. (2019) · Future Oncology · doi:10.2217/fon-2019-0101 · Cited by 44
Managing Ipilimumab-Induced Hypophysitis: Challenges and Current Therapeutic Strategies
Tsoli, M., Kaltsas, G., Angelousi, A. G., Alexandraki, K., Randeva, H. S., & Kassi, E. N. (2020) · Cancer Management and Research · doi:10.2147/cmar.s224791 · Cited by 41
Anti-PD1 and Anti-PDL1-Induced Hypophysitis: A Cohort Study of 17 Patients with Longitudinal Follow-Up
Levy, M., Abeillon, J., Dalle, S., Assaad, S., Borson‐Chazot, F., Disse, E., Raverot, G., & Cugnet‐Anceau, C. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9103280 · Cited by 41
Side effect management during immune checkpoint blockade using CTLA‐4 and PD‐1 antibodies for metastatic melanoma – an update
Kähler, K. C., Hassel, J. C., Heinzerling, L., Loquai, C., Thoms, K., Ugurel, S., Zimmer, L., & Gutzmer, R. (2020) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.14128 · Cited by 39
Clinical Presentation of Immune-Related Endocrine Adverse Events during Immune Checkpoint Inhibitor Treatment
Chieng, J. H. L., Htet, Z. W., Zhao, J. J., Tai, E. S., Tay, S. H., Huang, Y., Wong, A. S. C., & Yang, S. P. (2022) · Cancers · doi:10.3390/cancers14112687 · Cited by 40
Ipilimumab-induced hypophysitis, a single academic center experience
Snyders, T. P., Chakos, D., Swami, U., Latour, E. J., Chen, Y., Fleseriu, M., Milhem, M. M., Zakharia, Y., & Zahr, R. (2019) · Pituitary · doi:10.1007/s11102-019-00978-4 · Cited by 38
MECHANISMS IN ENDOCRINOLOGY: Autoimmune hypopituitarism: novel mechanistic insights
Takahashi, Y. (2020) · European Journal of Endocrinology · doi:10.1530/eje-19-1051 · Cited by 38
Isolated adrenocorticotropic hormone deficiency and thyroiditis associated with nivolumab therapy in a patient with advanced lung adenocarcinoma: a case report and review of the literature
Ohara, N., Kobayashi, M., Ohashi, K., Ito, R., Ikeda, Y., Kawaguchi, G., Yoneoka, Y., Hasegawa, G., & Takada, T. (2019) · Journal of Medical Case Reports · doi:10.1186/s13256-019-2002-2 · Cited by 37
Ipilimumab in melanoma
Specenier, P. M. (2016) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2016.1211936 · Cited by 38
Immune checkpoint inhibitor-related hypophysitis
Mizukoshi, T., Fukuoka, H., & Takahashi, Y. (2022) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2022.101668 · Cited by 36
Complete Response of a Patient With a Mismatch Repair Deficient Aggressive Pituitary Adenoma to Immune Checkpoint Inhibitor Therapy: A Case Report
Shah, S., Manzoor, S., Rothman, Y., Hagen, M. C., Pater, L. E., Golnik, K. C., Mahammedi, A., Lin, A. L., Bhabhra, R., Forbes, J. A., et al. (2022) · Neurosurgery · doi:10.1227/neu.0000000000002024 · Cited by 36
Isolated Adrenocorticotropic Hormone Deficiency Caused by Nivolumab in a Patient with Metastatic Lung Cancer
Takaya, K., Sonoda, M., Fuchigami, A., & Hiyoshi, T. (2017) · Internal Medicine · doi:10.2169/internalmedicine.8548-16 · Cited by 35
Pituitary dysfunction in granulomatosis with polyangiitis
Vega‐Beyhart, A., Medina-Rangel, I., Hinojosa‐Azaola, A., Fernández-Barrio, M., Vargas-Castro, A. S., García-Inciarte, L., Guzmán-Pérez, A., Victoria, T. R. T., Martínez‐Sánchez, F. D., Perez‐Guzman, M. C., et al. (2019) · Clinical Rheumatology · doi:10.1007/s10067-019-04735-7 · Cited by 35
Uncoupling Therapeutic Efficacy from Immune-Related Adverse Events in Immune Checkpoint Blockade
Hu, W., Wang, G., Wang, Y., Riese, M. J., & You, M. (2020) · iScience · doi:10.1016/j.isci.2020.101580 · Cited by 35
Iatrogenic adrenal insufficiency in adults
Martin‐Grace, J., Tomkins, M., O’Reilly, M., & Sherlock, M. (2024) · Nature Reviews Endocrinology · doi:10.1038/s41574-023-00929-x · Cited by 35
Multidisciplinary Clinical Approach to Cancer Patients with Immune-Related Adverse Events Induced by Checkpoint Inhibitors
Londoño, M., Reig, M., & on behalf of the RETOINMUNO Multidisciplinary Group (2020) · Cancers · doi:10.3390/cancers12113446 · Cited by 34
Fall in thyroid stimulating hormone (TSH) may be an early marker of ipilimumab-induced hypophysitis
Sousa, S. M. C. D., Sheriff, N., Tran, C. H., Menzies, A. M., Tsang, V., Long, G. V., & Tonks, K. T. T. (2018) · Pituitary · doi:10.1007/s11102-018-0866-6 · Cited by 34
In Situ Activation of Pituitary-Infiltrating T Lymphocytes in Autoimmune Hypophysitis
Lin, H.-H., Gutenberg, A., Chen, T., Tsai, N., Lee, C., Cheng, Y.-C., Cheng, W., Tzou, Y.-M., Caturegli, P., & Tzou, S. (2017) · Scientific Reports · doi:10.1038/srep43492 · Cited by 33
Hypoparathyroidism: An Uncommon Complication Associated With Immune Checkpoint Inhibitor Therapy
Kawkgi, O. M. E., Li, D., Kotwal, A., & Wermers, R. A. (2020) · Mayo Clinic Proceedings Innovations Quality & Outcomes · doi:10.1016/j.mayocpiqo.2020.07.006 · Cited by 33
Immune checkpoint inhibitor–associated hypercalcaemia
Izzedine, H., Chazal, T., Wanchoo, R., & Jhaveri, K. D. (2020) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaa326 · Cited by 32
Expert opinion on pituitary complications in immunotherapy
Briet, C., Albarel, F., Kuhn, E., Merlen, E., Chanson, P., & Cortet, C. (2018) · Annales d Endocrinologie · doi:10.1016/j.ando.2018.07.008 · Cited by 32
Diagnosis and management of immune‐related adverse effects of immune checkpoint therapy in the emergency department
Yeung, S. J., Qdaisat, A. Z., Chaftari, P. S., Lipe, D. N., Merlin, J., Rajha, E., Wechsler, A. H., Sandoval, M., Viets-Upchurch, J. M., Al‐Breiki, A., et al. (2020) · Journal of the American College of Emergency Physicians Open · doi:10.1002/emp2.12209 · Cited by 29
Endocrine Autoantibodies Determine Immune Checkpoint Inhibitor-induced Endocrinopathy: A Prospective Study
Labadzhyan, A., Wentzel, K. P., Hamid, O., Chow, K., Kim, S., Piro, L. D., & Melmed, S. K. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac161 · Cited by 31
A plea for the T2W MR sequence for pituitary imaging
Bonneville, J. (2018) · Pituitary · doi:10.1007/s11102-018-0928-9 · Cited by 30
Endocrine sequelae of immune checkpoint inhibitors
Ntali, G., Kassi, E. N., & Alevizaki, M. K. (2017) · HORMONES · doi:10.14310/horm.2002.1754 · Cited by 29
The changing clinical spectrum of endocrine adverse events in cancer immunotherapy
Chiloiro, S., Bianchi, A., Giampietro, A., Milardi, D., Marinis, L. D., & Pontecorvi, A. (2021) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2021.10.009 · Cited by 32
Isolated Adrenocorticotropic Hormone Deficiency and Severe Hypercalcemia After Destructive Thyroiditis in a Patient on Nivolumab Therapy With a Malignant Melanoma
Takebayashi, K., Ujiie, A., Kubo, M., Furukawa, S., Yamauchi, M., Shinozaki, H., Suzuki, T., Naruse, R., Hara, K., Tsuchiya, T., et al. (2018) · Journal of Clinical Medicine Research · doi:10.14740/jocmr3257w · Cited by 28
The imaging of immunotherapy-related hypophysitis and other pituitary lesions in oncology patients
Lasocki, A., Iravani, A., & Galligan, A. (2021) · Clinical Radiology · doi:10.1016/j.crad.2020.12.028 · Cited by 28
Spectrum of Clinical Presentations, Imaging Findings, and HLA Types in Immune Checkpoint Inhibitor–Induced Hypophysitis
Quandt, Z., Kim, S. J., Villanueva-Meyer, J. E., Coupe, C., Young, A., Kang, J. H., Yazdany, J., Schmajuk, G., Rush, S., Ziv, E., et al. (2023) · Journal of the Endocrine Society · doi:10.1210/jendso/bvad012 · Cited by 28

Authors: Faje, A.
Affiliations: Harvard University (US)
Corresponding author: Faje, Alexander
ORCID: Faje, Alexander
Venue: Pituitary
Publisher: Springer Science and Business Media LLC
Published: 2015-07-18
Volume: 19
Issue: 1
Pages: 82-92
ISSN: 1386-341X (ISSN-L)
1573-7403
DOI: 10.1007/s11102-015-0671-4
OpenAlex: W1185432402
Cited by: 326
References: 88
Citations by year: 2026: 12 · 2025: 25 · 2024: 16 · 2023: 29 · 2022: 32 · 2021: 37 · 2020: 49 · 2019: 36 · 2018: 41 · 2017: 31 · 2016: 18
FWCI: 3.22
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
Locations: Pituitary (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
Keywords: immune-related adverse events, immunotherapy, autoimmune hypophysitis, metastatic melanoma, endocrine adverse events, risk factors
MeSH terms: Hypophysitis, Ipilimumab, Antibodies, Monoclonal, Humans, Immunotherapy, CTLA-4 Antigen

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks